Clearmind’s Patent Win and $0.8M Financing Ignite 56% Share Rally
By ATTN Desk · Editorial oversight: Sean Han
Introduction
CLEARMIND MEDICINE INC (Nasdaq: CMND) is a Vancouver-based biotechnology company developing psychedelic-inspired therapeutics to address binge behaviour and mental health disorders such as alcohol use disorder, binge eating, and depression. Its lead compound, 5-Methoxy-2-aminoindane (MEAI), is designed as a non-hallucinogenic neuroplastogen intended for self-administration.
Corporate Structure
Founded in 2021, Clearmind employs between 11 and 50 people across research, clinical operations, and corporate functions. The leadership team is headed by CEO Dr. Adi Zuloff-Shani, who has over 20 years of experience in strategic and operational roles within the regulated healthcare sector. The Scientific Advisory Board includes Prof. Henry R. Kranzler, MD, PhD, Director of the Center for Studies of Addiction at the University of Pennsylvania’s Perelman School of Medicine.
Psychedelic therapy by Alexander Grey
Developments and News
- On November 12, 2025, Clearmind filed a notice of patent publication for a depression treatment based on MEAI, marking a development in its intellectual property portfolio.
- On November 13, 2025, the company announced a registered direct offering of 958,222 common shares at US $0.20 per share and up to 2,984,146 pre-funded warrants at US $0.1999 each (exercise price US $0.0001). Gross proceeds are expected to be approximately US $0.788 million.
Financial and Strategic Analysis
As of November 13, 2025, the share price closed at US $0.4844, an increase of 56.11% on the Nasdaq, with a trading volume of 4,954,151 shares. Selected metrics:
| Metric | Value |
|---|---|
| Market Capitalization | US $3.72 million |
| Total Cash (most recent qtr) | US $3.5 million |
| Total Debt/Equity (mrq) | 2.67% |
| EPS (TTM) | –0.75 |
| Net Income (TTM) | –US $4.05 million |
| Beta (5-Year Monthly) | –1.24 |
The proceeds from the direct offering will support operating costs, research and development, clinical and pre-clinical testing, working capital, and potential acquisitions. The exercise of warrants is subject to a beneficial ownership limit of 4.99% for each holder.
Market Position and Industry Context
Clearmind targets a combined U.S. market of over US $442 billion for substance and alcohol abuse. Of the 1,302 registered clinical trials investigating psychedelics, only 21 (approximately 1.6%) focus on alcohol-related treatments, indicating a low level of competition in this niche. The non-hallucinogenic profile and self-administration design of MEAI differentiate it from other psychedelic candidates.
tl;dr
On November 12 and 13, 2025, Clearmind Medicine announced a patent publication for its MEAI depression treatment and completed a direct offering to raise approximately US $0.788 million. The new capital will fund ongoing research and development, clinical trials, and corporate expenses. The stock price increased by 56.11% to US $0.4844, reflecting market response to the intellectual property and financing announcements. Future developments include the advancement of MEAI through Phase I/IIa trials and the expansion of its intellectual property portfolio.